Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Brough

Showing results (11-20 of 66) with videos related to

Pageof 7
Sort By:
Disability and Rehabilitation. Assistive Technology|March 10, 2025
Assistive technology at work: a metasynthesis of the perspectives of people with spinal cord injury/damageJessie Mitchell, Jessica O'Loghlen, Emily Bray, et al.
Molecular Cancer Therapeutics|February 13, 2015
Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR PathwaysMarieke Aarts, Ilirjana Bajrami, Maria T Herrera-Abreu, et al.
The EMBO Journal|April 5, 2008
A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitorNicholas C Turner, Christopher J Lord, Elizabeth Iorns, et al.
Oncogene|June 20, 2018
Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancerRachel Brough, Aditi Gulati, Syed Haider, et al.
Science Advances|March 26, 2025
Proteogenomic discovery of <i>RB1</i>-defective phenocopy in cancer predicts disease outcome, response to treatment, and therapeutic targetsJacopo Iacovacci, Rachel Brough, Fatemeh Ahmadi Moughari, et al.
British Journal of Cancer|April 10, 2024
Pathway-based signatures predict patient outcome, chemotherapy benefit and synthetic lethal dependencies in invasive lobular breast cancerJohn Alexander, Koen Schipper, Sarah Nash, et al.
Nature|February 12, 2008
Resistance to therapy caused by intragenic deletion in BRCA2Stacey L Edwards, Rachel Brough, Christopher J Lord, et al.
Plos One|February 17, 2016
CDK1 Is a Synthetic Lethal Target for KRAS Mutant TumoursSara Costa-Cabral, Rachel Brough, Asha Konde, et al.
Disability and Rehabilitation|March 10, 2025
Setting me up or holding me back? Perspectives of people with spinal cord injury on rehabilitation supports at inpatient discharge and 3-months post-dischargeEmily Bray, Rachel Brough, Rachel Jones, et al.
Plos One|April 21, 2017
Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant TumoursSara Costa-Cabral, Rachel Brough, Asha Konde, et al.
Pageof 7

Showing results (11-20 of 66) with videos related to

Sort By:
Pageof 7
Disability and Rehabilitation. Assistive Technology|March 10, 2025
Assistive technology at work: a metasynthesis of the perspectives of people with spinal cord injury/damageJessie Mitchell, Jessica O'Loghlen, Emily Bray, et al.
Molecular Cancer Therapeutics|February 13, 2015
Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR PathwaysMarieke Aarts, Ilirjana Bajrami, Maria T Herrera-Abreu, et al.
The EMBO Journal|April 5, 2008
A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitorNicholas C Turner, Christopher J Lord, Elizabeth Iorns, et al.
Oncogene|June 20, 2018
Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancerRachel Brough, Aditi Gulati, Syed Haider, et al.
Science Advances|March 26, 2025
Proteogenomic discovery of <i>RB1</i>-defective phenocopy in cancer predicts disease outcome, response to treatment, and therapeutic targetsJacopo Iacovacci, Rachel Brough, Fatemeh Ahmadi Moughari, et al.
British Journal of Cancer|April 10, 2024
Pathway-based signatures predict patient outcome, chemotherapy benefit and synthetic lethal dependencies in invasive lobular breast cancerJohn Alexander, Koen Schipper, Sarah Nash, et al.
Nature|February 12, 2008
Resistance to therapy caused by intragenic deletion in BRCA2Stacey L Edwards, Rachel Brough, Christopher J Lord, et al.
Plos One|February 17, 2016
CDK1 Is a Synthetic Lethal Target for KRAS Mutant TumoursSara Costa-Cabral, Rachel Brough, Asha Konde, et al.
Disability and Rehabilitation|March 10, 2025
Setting me up or holding me back? Perspectives of people with spinal cord injury on rehabilitation supports at inpatient discharge and 3-months post-dischargeEmily Bray, Rachel Brough, Rachel Jones, et al.
Plos One|April 21, 2017
Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant TumoursSara Costa-Cabral, Rachel Brough, Asha Konde, et al.
Pageof 7